Risk factor
High price volatility
Profitability factor
Slightly undervalued vs peers
About
Hefei Lifeon Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a wide array of pharmaceutical goods. Its product portfolio encompasses active pharmaceutical ingredients (APIs) such as succimer, urea, paeonol, felodipine, doxazosin mesylate, zofenopril calcium, troxerutin, and sodium 2,3-dimercapto-1-propanesulfonate. The company also manufactures various medicinal preparations, including felodipine sustained-release tablets, doxazosin mesylate extended-release tablets, melbinum glipizide tablets, yiqihewei capsules, kunning granules, armillariella oral solution, paeonol ointment, urea and vitamin E cream, Kecuo Yintong gel, and Compound Golden Larch bark gel. Additionally, Hefei Lifeon Pharmaceutical supplies plant extracts like clove oil, evening primrose oil, herba clinopodii P.E, quercetin, and dihydroquercetin. Beyond its manufacturing operations, the company operates a retail chain for pharmaceuticals. Established in 2002, Hefei Lifeon Pharmaceutical Co., Ltd. is headquartered in Hefei, China.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, reasonably